Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

News Daily News

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

December 08, 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many

News Conference News AHA 2017

Low High-Sensitivity Troponin I Cutoff May Allow Discharge From ED for Many

November 11, 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

November 09, 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

News Conference News TCT 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

November 02, 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

October 30, 2017

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

TCTMD’s Top 10 Most Popular Stories for October 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

October 29, 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

October 20, 2017

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

Same-Same but Different? Noninferiority Trials Need a Revamp, NEJM Review Argues

News Daily News

Same-Same but Different? Noninferiority Trials Need a Revamp, NEJM Review Argues

October 06, 2017

Switching to E-Cigarettes From Tobacco Could Drastically Curb Premature Death

News Daily News

Switching to E-Cigarettes From Tobacco Could Drastically Curb Premature Death

October 04, 2017

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

News Daily News

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

September 14, 2017

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

September 07, 2017

Evolocumab Not Cost-Effective at Current List Price

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

Costs Up, Usage Down: Hospitals Curtailed Use of CV Meds When Prices Soared

News Daily News

Costs Up, Usage Down: Hospitals Curtailed Use of CV Meds When Prices Soared

August 15, 2017

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

July 24, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.